KIT and gastrointestinal stromal tumor: These include NF‐2 mutation in meningioma [335], KIT 11 mutation in GIST [336], angiogenesis‐related genomic risk score in bladder cancer [172], MDM2 amplification in retroperitoneal well‐differentiated liposarcomas and lipomas [337, 338], EGFR mutation in brain adenocarcinoma [339], TP53 and MYCN alterations in endometrial cancer and neuroblastoma [340, 341], immunology subgroups in cholangiocarcinoma [330], as well as several key gene alterations in intrahepatic cholangiocarcinoma and papillary thyroid carcinoma [342, 343].